Skip to main content

Table 1 Patients Characteristics (n = 29)

From: Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience

 

Details

Patients (%)

Age

Median (range), years

72 (53–91)

Time between ADT and ARTT

Median (range), months

48.1 (12.1–123.3)

RT techniques

3DRT

24 (82.7%)

SBRT

5 (17.3%)

ARTT

Abiraterone

21 (72.4%)

Enzalutamide

8 (27.6%)

Treatment line

I

17 (58.6%)

II-III

12 (41.4%)

PSA after 1 month from the start of ARTT

Median (range), ng/ml

3.02 (0.02–100)

≤50% reduction

5 (17.2%)

> 50% reduction

24 (82.8%)

RT timing respect the start of ARTT

<  6 months

15 (51.7%)

> 6 months

14 (48.3%)

RT sites

 

Lesions (%)

 

Bones

31 (83%)

 

Lung

2 (5.5%)

 

Lymphnodes

2 (5.5%)

 

Prostatic Bed

2 (5.5%)

  1. ADT Androgen deprivation therapy, ARTT Androgen receptor targeted therapy
  2. RT Radiotherapy, 3DRT Conformal radiotherapy, SBRT Stereotactic body
  3. Radiation therapy, PSA Prostatic specific antigen